Recent studies looking at TP53 alterations in rhabdomyosarcoma (RMS) patients show that TP53 mutations are correlated with an increased risk of developing RMS and a worse prognosis (Casey et al., 2021; Shern et al., 2021); however, the role for specific TP53 variants in sarcoma progression remains to be defined. Here, TP53 is linked to sarcoma.